Drugs / INDENEBART
INDENEBART
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04449484 | Aug 2020 → Jan 2022 | Parkinson disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03272165 | Oct 2017 → Mar 2021 | Parkinson disease | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05526391 | Nov 2022 → Jul 2025 | multiple system atrophy | Takeda | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-08-29 | AstraZeneca | AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson’s disease astrazeneca.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INDENEBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068461 ↗ |
| Known as | MEDI1341 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04449484 ↗ |
| Known as | TAK-341 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05526391 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068461 ↗ |
| Route | Intravenous | “single 60 minute intravenous infusion of MEDI1341 or placebo” NCT03272165 ↗ |